December 21, 2010

Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

PUBLICATION: 
Am J Manag Care. 2010 Dec 1;16(12):e333-42.

AUTHORS: 
Chen E., Tong K.B., Malin J.L.

SUMMARY: 
70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use and an increase in life expectancy when applied appropriately.

Read more: Chen et al_2010_American Journal of Managed Care_Cost-effectiveness of MammaPrint